Raymond James Financial
CRBP icon

Raymond James Financial’s Corbus Pharmaceuticals CRBP Stock Holding History

Raymond James Financial’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-434
Closed -$2.99K – 5337
2025
Q2 		$2.99K Buy
+434
New +$3.15K ﹤0.01% 6313

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Raymond James Financial's CRBP Position: Q3 2025 in Review

Raymond James Financial sold out of Corbus Pharmaceuticals (CRBP) in Q3 2025, closing a stake of 434 shares — an estimated $2.99K sold.

Raymond James Financial first reported a position in CRBP in Q2 2025 and held it in 1 quarter. The position peaked at $2.99K in Q2 2025. 81 funds tracked by Wall St. Rank hold CRBP as of Q3 2025.

  • Raymond James Financial reported no remaining Corbus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 434 Corbus Pharmaceuticals shares in Q3 2025, an estimated $2.99K.
  • Raymond James Financial first reported a position in Corbus Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Corbus Pharmaceuticals position peaked at $2.99K in Q2 2025.
  • 81 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.